Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.

PURPOSE The purpose of this study was to determine the frequency and spectrum of inosine monophosphate dehydrogenase type I (IMPDH1) mutations associated with autosomal dominant retinitis pigmentosa (RP), to determine whether mutations in IMPDH1 cause other forms of inherited retinal degeneration, and to analyze IMPDH1 mutations for alterations in enzyme activity and nucleic acid binding. METHODS The coding sequence and flanking intron/exon junctions of IMPDH1 were analyzed in 203 patients with autosomal dominant RP (adRP), 55 patients with autosomal recessive RP (arRP), 7 patients with isolated RP, 17 patients with macular degeneration (MD), and 24 patients with Leber congenital amaurosis (LCA). DNA samples were tested for mutations by sequencing only or by a combination of single-stranded conformational analysis and by sequencing. Production of fluorescent reduced nicotinamide adenine dinucleotide (NADH) was used to measure enzymatic activity of mutant IMPDH1 proteins. The affinity and the specificity of mutant IMPDH1 proteins for single-stranded nucleic acids were determined by filter-binding assays. RESULTS Five different IMPDH1 variants, Thr116Met, Asp226Asn, Val268Ile, Gly324Asp, and His 372Pro, were identified in eight autosomal dominant RP families. Two additional IMPDH1 variants, Arg105Trp and Asn198Lys, were found in two patients with isolated LCA. None of the novel IMPDH1 mutants identified in this study altered the enzymatic activity of the corresponding proteins. In contrast, the affinity and/or the specificity of single-stranded nucleic acid binding were altered for each IMPDH1 mutant except the Gly324Asp variant. CONCLUSIONS Mutations in IMPDH1 account for approximately 2% of families with adRP, and de novo IMPDH1 mutations are also rare causes of isolated LCA. This analysis of the novel IMPDH1 mutants substantiates previous reports that IMPDH1 mutations do not alter enzyme activity and demonstrates that these mutants alter the recently identified single-stranded nucleic acid binding property of IMPDH. Studies are needed to further characterize the functional significance of IMPDH1 nucleic acid binding and its potential relationship to retinal degeneration.

[1]  G. Fish,et al.  Phenotypic characterization of a large family with RP10 autosomal-dominant retinitis pigmentosa: an Asp226Asn mutation in the IMPDH1 gene. , 2005, American journal of ophthalmology.

[2]  L. Hedstrom,et al.  Autosomal dominant retinitis pigmentosa mutations in inosine 5'-monophosphate dehydrogenase type I disrupt nucleic acid binding. , 2005, The Biochemical journal.

[3]  T. L. McGee,et al.  Screen of the IMPDH1 gene among patients with dominant retinitis pigmentosa and clinical features associated with the most common mutation, Asp226Asn. , 2005, Investigative ophthalmology & visual science.

[4]  G. Fishman,et al.  A novel IMPDH1 mutation (Arg231Pro) in a family with a severe form of autosomal dominant retinitis pigmentosa. , 2004, Ophthalmology.

[5]  L. Hedstrom,et al.  Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo. , 2004, The Biochemical journal.

[6]  L. Hedstrom,et al.  Substitution of the conserved Arg-Tyr dyad selectively disrupts the hydrolysis phase of the IMP dehydrogenase reaction. , 2004, Biochemistry.

[7]  I. Alberts,et al.  On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. , 2004, Human molecular genetics.

[8]  A. Kennan,et al.  Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. , 2002, Human molecular genetics.

[9]  Seth Blackshaw,et al.  Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. , 2002, Human molecular genetics.

[10]  Marianne Haim,et al.  Epidemiology of retinitis pigmentosa in Denmark. , 2002, Acta ophthalmologica Scandinavica. Supplement.

[11]  L. Hedstrom,et al.  IMP dehydrogenase: mechanism of action and inhibition. , 1999, Current medicinal chemistry.

[12]  C. Freund,et al.  A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription-factor gene. , 1998, American journal of human genetics.

[13]  B. Mitchell,et al.  Regulation of the Human Inosine Monophosphate Dehydrogenase Type I Gene , 1997, The Journal of Biological Chemistry.

[14]  E. Berson,et al.  Retinitis pigmentosa: unfolding its mystery. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  V. Sheffield,et al.  Phenotypic variation including retinitis pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of codon 153 or 154 of the peripherin/RDS gene. , 1993, Archives of ophthalmology.

[16]  Alan Bird,et al.  Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy , 1993, Nature Genetics.

[17]  S. Daiger,et al.  Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies , 2001, Human mutation.

[18]  Y. Natsumeda,et al.  Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). , 1994, Life sciences.